Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
VYNE Therapeutics Shares Disappointing Data From Atopic Dermatitis Trial
VYNE Therapeutics Inc (NASDAQ: VYNE) has announced results from the Phase 2a segment of Phase 1b/2a trial evaluating FMX114 for mild-to-moderate atopic dermatitis.
VYNE Therapeutics Concludes Patient Enrolment in Mid-Stage Study Of Skin Inflammation Candidate
VYNE Therapeutics Inc. (NASDAQ: VYNE) has concluded patient enrollment in the Phase 2a study of of its drug candidate FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD).
VYNE Therapeutics Shares Gain After Positive Atopic Dermatitis Trial Of FMX114
VYNE Therapeutics Inc (NASDAQ:VYNE) announced positive efficacy results from the Phase 1b segment of Phase 1b/2a trial of FMX114 in mild-to-moderate…
12 Health Care Stocks Moving In Thursday’s Pre-Market Session
Gainers
IMAC Holdings (NASDAQ:IMAC) shares increased by 60.0% to $1.6 during Thursday's pre-market session. The market value of their outstanding shares is at $41.9 million.
VYNE Therapeutics Shares Jump On Encouraging Preclinical Data From VYN201 Program In Rheumatoid Arthritis
VYNE Therapeutics Inc (NASDAQ:VYNE) announced positive preclinical data from its VYN201 program in the rheumatoid arthritis (RA) animal model. The Company…
VYNE Reports Preclinical Data For Intra-Articular Injection Of Pan-BET Inhibitor, VYN201, In An In Vivo Model of Rheumatoid Arthritis
VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company focused on developing proprietary, innovative, and differentiated therapies for the treatment of
Recap: VYNE Therapeutics Q4 Earnings
VYNE Therapeutics (NASDAQ:VYNE) reported its Q4 earnings results on Thursday, March 17, 2022 at 08:00 AM.
Here's what investors need to know about the announcement.
VYNE Therapeutics’ BET Inhibitor Shows Encouraging Preclinical Action In Skin Disorder
VYNE Therapeutics Inc (NASDAQ: VYNE) has